Bonus BioGroup Ltd. (BONS)

Overview

Bonus BioGroup Ltd. is a pioneering biotechnology entity focused on the forefront of tissue engineering and cell therapy. Established in 1981 and transitioning from its original identity as Oceana Advanced Industries Ltd., the company has carved a niche in clinical-stage biotech innovation from its base in Haifa, Israel. Dedicated to addressing some of the most pressing medical challenges, Bonus BioGroup's endeavors in regenerative medicine and cell therapy represent a confluence of science and hope for those afflicted with various conditions requiring novel, regenerative solutions.

Products and Services

• BonoFill for Bone Tissue Regeneration

  BonoFill represents a significant leap towards addressing maxillofacial and orthopedic challenges, currently undergoing a Phase II clinical trial. This innovative product aims to revolutionize bone tissue regeneration, offering a beacon of hope for patients with bone deficits seeking restorative solutions beyond the limitations of traditional treatments.

• MesenCure for COVID-related Complications

  In response to the global COVID-19 pandemic, Bonus BioGroup introduced MesenCure, a promising treatment for patients suffering from pneumonia and ARDS triggered by the virus. Now in Phase III trials, MesenCure embodies the company's rapid response and commitment to leveraging their cell therapy expertise to combat urgent, life-threatening conditions.

• BonoFill for Osteoporosis

  Expanding the scope of their regenerative solutions, Bonus BioGroup is developing an adaptation of BonoFill targeted at the osteoporosis market. This version aims to provide bone augmentation for patients battling the frailties of weakened bones, potentially revolutionizing the treatment paradigm for osteoporosis through regenerative medicine.

• MesenCure for Inflammations and Tissue Damage Beyond COVID

  An extension of the therapeutic application of MesenCure is in development for treating a variety of inflammations and tissue damages. This venture underlines the flexibility and potential of MesenCure as a cell therapy platform beyond its initial application for COVID-related ailments.

• Vascularized Bone Grafts

  Within its ambitious pipeline, Bonus BioGroup is exploring the potential of vascularized bone grafts. This innovation aims at addressing the complex requirements of bone repair, including the critical aspect of vascularization necessary for successful grafting procedures and enhanced recovery outcomes.

• Soft Tissue Grafts

  Complementing its bone regeneration efforts, the company is also venturing into the development of soft tissue grafts. This move signifies a broader pursuit towards comprehensive regenerative therapies, potentially offering novel solutions for repairing and replacing damaged soft tissues.